Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

About this update from Acadia Pharmaceuticals Inc.

SAN DIEGO, April 17, 2026--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults with Rett syndrome in routine clinical practice. In support of NUPLAZID® (pimavanserin) in Parkinson’s disease psychosis (PDP), Acadia will present exploratory analyses evaluating heterogeneity in treatment response trajectories and the impact of baseline sleep disturbances among PDP patients treated with pimavanserin. The Company is also debuting translational and pharmacokinetic research supporting the continued development of ACP-711, an investigational drug, for essential tremor. Collectively, these data reflect Acadia’s ongoing commitment to advancing scientific knowledge across a wide range of neurological conditions. AAN Poster Presentations About DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide) Trofinetide is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor-1. The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity signals.1 Indication and Important Safety Information for DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide) Indication DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. Important Safety Information DAYBUE is available as an oral solution (200 mg/mL). DAYBUE STIX for oral solution powder is available in 5,000 mg, 6,000 mg, and 8,000 mg packets. Please read the full Prescribing Information also available at DAYBUEhcp.com. About NUPLAZID® (pimavanserin) Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or ad...

View stock analysis, news, and events for Acadia Pharmaceuticals Inc.